Biotage AB - Asset Resilience Ratio
Biotage AB (BIOT) has an Asset Resilience Ratio of 8.92% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of Biotage AB to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2024)
This chart shows how Biotage AB's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Biotage AB total assets.
Liquid Assets Composition Over Time
This chart breaks down Biotage AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Biotage AB long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr420.00 Million | 8.92% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr420.00 Million | 8.92% |
Asset Resilience Insights
- Limited Liquidity: Biotage AB maintains only 8.92% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Biotage AB Industry Peers by Asset Resilience Ratio
Compare Biotage AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Alcon AG
SW:ALC |
Medical Instruments & Supplies | 0.26% |
|
STAAR Surgical Company
NASDAQ:STAA |
Medical Instruments & Supplies | 6.93% |
|
BMC Medical Co. Ltd. A
SHE:301367 |
Medical Instruments & Supplies | 47.31% |
|
SWS Hemodialysis Care Co. Ltd. A
SHG:688410 |
Medical Instruments & Supplies | 38.45% |
|
Vizionfocus Inc.
TW:4771 |
Medical Instruments & Supplies | 3.24% |
|
Spineway
PA:ALSPW |
Medical Instruments & Supplies | -0.24% |
|
Safe Orthopaedics SA
PA:ALSAF |
Medical Instruments & Supplies | 2.20% |
|
Ansell Ltd
AU:ANN |
Medical Instruments & Supplies | 7.53% |
Annual Asset Resilience Ratio for Biotage AB (2000–2024)
The table below shows the annual Asset Resilience Ratio data for Biotage AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 8.50% | Skr434.00 Million ≈ $46.71 Million |
Skr5.10 Billion ≈ $549.27 Million |
-3.46pp |
| 2023-12-31 | 11.97% | Skr590.00 Million ≈ $63.49 Million |
Skr4.93 Billion ≈ $530.65 Million |
-6.89pp |
| 2022-12-31 | 18.85% | Skr441.00 Million ≈ $47.46 Million |
Skr2.34 Billion ≈ $251.71 Million |
+3.44pp |
| 2021-12-31 | 15.41% | Skr307.00 Million ≈ $33.04 Million |
Skr1.99 Billion ≈ $214.37 Million |
-10.35pp |
| 2020-12-31 | 25.76% | Skr369.49 Million ≈ $39.76 Million |
Skr1.43 Billion ≈ $154.37 Million |
+11.99pp |
| 2019-12-31 | 13.77% | Skr183.87 Million ≈ $19.79 Million |
Skr1.34 Billion ≈ $143.74 Million |
-3.69pp |
| 2018-12-31 | 17.46% | Skr175.17 Million ≈ $18.85 Million |
Skr1.00 Billion ≈ $107.96 Million |
-5.37pp |
| 2017-12-31 | 22.83% | Skr172.86 Million ≈ $18.60 Million |
Skr757.20 Million ≈ $81.49 Million |
+4.72pp |
| 2016-12-31 | 18.11% | Skr125.88 Million ≈ $13.55 Million |
Skr695.20 Million ≈ $74.81 Million |
+10.50pp |
| 2008-12-31 | 7.61% | Skr98.80 Million ≈ $10.63 Million |
Skr1.30 Billion ≈ $139.79 Million |
-2.97pp |
| 2002-12-31 | 10.57% | Skr71.70 Million ≈ $7.72 Million |
Skr678.04 Million ≈ $72.97 Million |
-12.34pp |
| 2001-12-31 | 22.91% | Skr194.03 Million ≈ $20.88 Million |
Skr846.82 Million ≈ $91.13 Million |
-15.89pp |
| 2000-12-31 | 38.81% | Skr370.00 Million ≈ $39.82 Million |
Skr953.47 Million ≈ $102.61 Million |
-- |
About Biotage AB
Biotage AB (publ) provides solutions and products in the areas of drug discovery and development, analytical testing, and water and environmental testing. The company offers organic and peptide synthesis solutions; flash chromotherapy, evaporation, parallel peptide purification, and work-up products; flash systems and accessories, and normal and reversed phase cartridges; sample preparation produ… Read more